可溶性白细胞介素-6受体（sIL-6R），多发性骨髓瘤的一种新的预后因素。

Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma.

作者信息

Kyrtsonis M C, Dedoussis G, Zervas C, Perifanis V, Baxevanis C, Stamatelou M, Maniatis A

机构信息

Laboratory Haematology and Transfusion Medicine, University of Patras Medical School, Greece.

出版信息

Br J Haematol. 1996 May;93(2):398-400. doi: 10.1046/j.1365-2141.1996.4721018.x.

DOI:10.1046/j.1365-2141.1996.4721018.x

PMID:8639436

Abstract

sIL-6R is a 55 kD soluble molecule mediating the interleukin-6 (IL-6) signal through the IL-6 receptor-associated transmembrane signal transducer, gp130. It has recently been suggested that sIL-6R serum levels may reflect disease severity in multiple myeloma (MM). We determined sIL-6R serum levels in 25 normal controls (NC) and in 80 MM patients at diagnosis and during the course of the disease. Measurements were done by ELISA. In NC, sIL-6R levels ranged from 14 to 40 ng/ml (median 28 ng/ml) whereas in MM patients the range was 10-200 ng/ml (median 38 ng/ml) (P<0.01). 61 patients entered remission and 19 were resistant. Median sIL-6R value at diagnosis was 36 ng/ml (10-120) in responding patients, and 82 ng/ml (20-200) in non-responding patients (P<0.001). During a follow-up from 12 to 89 months, sIL-6R values remained more or less stable in most patients. High sIL-6R levels correlated with poor survival.

摘要

可溶性白细胞介素-6受体（sIL-6R）是一种55千道尔顿的可溶性分子，它通过白细胞介素-6受体相关跨膜信号转导分子gp130介导白细胞介素-6（IL-6）信号。最近有研究表明，sIL-6R血清水平可能反映多发性骨髓瘤（MM）的疾病严重程度。我们测定了25名正常对照者（NC）以及80例MM患者在诊断时和疾病过程中的sIL-6R血清水平。检测采用酶联免疫吸附测定（ELISA）法。在正常对照者中，sIL-6R水平在14至40纳克/毫升之间（中位数为28纳克/毫升），而在MM患者中，该范围为10至200纳克/毫升（中位数为38纳克/毫升）（P<0.01）。61例患者进入缓解期，19例耐药。缓解患者诊断时sIL-6R的中位值为36纳克/毫升（10至120），未缓解患者为82纳克/毫升（20至200）（P<0.001）。在12至89个月的随访期间，大多数患者的sIL-6R值或多或少保持稳定。高sIL-6R水平与较差的生存率相关。